Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients
Objectives: Sorafenib is the standard first-line treatment for HCC. No sufficient data exists regarding its efficacy in the Egyptian population being a costly medication that is not endorsed by insurance and hence is not used in most institutions. This study aimed to evaluate the overall survival [O...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ain Shams University
2020-12-01
|
| Series: | Archives of Pharmaceutical Sciences Ain Shams University |
| Subjects: | |
| Online Access: | https://aps.journals.ekb.eg/article_135136.html |
| _version_ | 1818368309314191360 |
|---|---|
| author | Noha Salah El Baghdady Lamia Elwakeel Mahmoud Ellithy Nawal Hussein Sara Shahin Abdel Rahman El Naggar |
| author_facet | Noha Salah El Baghdady Lamia Elwakeel Mahmoud Ellithy Nawal Hussein Sara Shahin Abdel Rahman El Naggar |
| author_sort | Noha Salah El Baghdady |
| collection | DOAJ |
| description | Objectives: Sorafenib is the standard first-line treatment for HCC. No sufficient data exists regarding its efficacy in the Egyptian population being a costly medication that is not endorsed by insurance and hence is not used in most institutions. This study aimed to evaluate the overall survival [OS], progression-free survival [PFS] and quality of life [QOL] of Egyptian HCC patients receiving sorafenib versus supportive care.
Design: A Prospective cohort observational study.
Setting: Electricity Hospital, Medical Oncology Department-Ain Shams University, and Nasser Institute for Research and Treatment, Egypt
Subjects: Fifty-five patients with HCC were eligible for enrolment in the trial. Eligible HCC patients were stratified into one of two groups based on institutions’ protocols for HCC treatment. Group (1) received supportive care [n= 20] and Group (2) received sorafenib [n=35]; the patients follow up were continued for one year after diagnosis.
Main outcome measures: Patients’ survival, PFS, and QOL.
Results: The one-year survival rates were 0.0% and 75.5% [p= 0.008] for group (1) versus group (2), respectively. The median PFS was 5 months and 12 months for group (1) versus group (2), respectively [p= 0.008]. The QOL of the sorafenib group was better than the supportive care group [p = 0.047]. The most common side effects with sorafenib were diarrhoea [42.8%] and hand-foot syndrome [34.2%]. In the sorafenib group, 48.57 % of the patients were requiring dose reduction.
Conclusion: Sorafenib was an effective first-line therapy in Egyptian HCC patients with a superior QOL, OS and PFS than those receiving supportive care. |
| first_indexed | 2024-12-13T23:05:54Z |
| format | Article |
| id | doaj.art-0ce21cff2cdc49c4b346260ff993f749 |
| institution | Directory Open Access Journal |
| issn | 2356-8380 2356-8399 |
| language | English |
| last_indexed | 2024-12-13T23:05:54Z |
| publishDate | 2020-12-01 |
| publisher | Ain Shams University |
| record_format | Article |
| series | Archives of Pharmaceutical Sciences Ain Shams University |
| spelling | doaj.art-0ce21cff2cdc49c4b346260ff993f7492022-12-21T23:28:17ZengAin Shams UniversityArchives of Pharmaceutical Sciences Ain Shams University2356-83802356-83992020-12-0142224236https://dx.doi.org/10.21608/aps.2020.45180.1043Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma PatientsNoha Salah El Baghdady0Lamia Elwakeel1Mahmoud Ellithy2 Nawal Hussein3Sara Shahin4Abdel Rahman El Naggar5Clinical Pharmacy department, New Giza School of Pharmacy, EgyptDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, POX 11566, Cairo, EgyptDepartment of Oncology, Faculty of Medicine Ain Shams University, EgyptMedical Oncology Department, Electricity Hospital, Cairo, Egypt.Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, POX 11566, Cairo, EgyptClinical Pharmacology Department, Faculty of Medicine, Cairo University, EgyptObjectives: Sorafenib is the standard first-line treatment for HCC. No sufficient data exists regarding its efficacy in the Egyptian population being a costly medication that is not endorsed by insurance and hence is not used in most institutions. This study aimed to evaluate the overall survival [OS], progression-free survival [PFS] and quality of life [QOL] of Egyptian HCC patients receiving sorafenib versus supportive care. Design: A Prospective cohort observational study. Setting: Electricity Hospital, Medical Oncology Department-Ain Shams University, and Nasser Institute for Research and Treatment, Egypt Subjects: Fifty-five patients with HCC were eligible for enrolment in the trial. Eligible HCC patients were stratified into one of two groups based on institutions’ protocols for HCC treatment. Group (1) received supportive care [n= 20] and Group (2) received sorafenib [n=35]; the patients follow up were continued for one year after diagnosis. Main outcome measures: Patients’ survival, PFS, and QOL. Results: The one-year survival rates were 0.0% and 75.5% [p= 0.008] for group (1) versus group (2), respectively. The median PFS was 5 months and 12 months for group (1) versus group (2), respectively [p= 0.008]. The QOL of the sorafenib group was better than the supportive care group [p = 0.047]. The most common side effects with sorafenib were diarrhoea [42.8%] and hand-foot syndrome [34.2%]. In the sorafenib group, 48.57 % of the patients were requiring dose reduction. Conclusion: Sorafenib was an effective first-line therapy in Egyptian HCC patients with a superior QOL, OS and PFS than those receiving supportive care.https://aps.journals.ekb.eg/article_135136.htmlhepatocellular carcinomasorafenibbest supportive careefficacysafetyquality of life |
| spellingShingle | Noha Salah El Baghdady Lamia Elwakeel Mahmoud Ellithy Nawal Hussein Sara Shahin Abdel Rahman El Naggar Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients Archives of Pharmaceutical Sciences Ain Shams University hepatocellular carcinoma sorafenib best supportive care efficacy safety quality of life |
| title | Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients |
| title_full | Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients |
| title_fullStr | Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients |
| title_full_unstemmed | Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients |
| title_short | Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients |
| title_sort | efficacy and safety of sorafenib versus supportive care in egyptian advanced hepatocellular carcinoma patients |
| topic | hepatocellular carcinoma sorafenib best supportive care efficacy safety quality of life |
| url | https://aps.journals.ekb.eg/article_135136.html |
| work_keys_str_mv | AT nohasalahelbaghdady efficacyandsafetyofsorafenibversussupportivecareinegyptianadvancedhepatocellularcarcinomapatients AT lamiaelwakeel efficacyandsafetyofsorafenibversussupportivecareinegyptianadvancedhepatocellularcarcinomapatients AT mahmoudellithy efficacyandsafetyofsorafenibversussupportivecareinegyptianadvancedhepatocellularcarcinomapatients AT nawalhussein efficacyandsafetyofsorafenibversussupportivecareinegyptianadvancedhepatocellularcarcinomapatients AT sarashahin efficacyandsafetyofsorafenibversussupportivecareinegyptianadvancedhepatocellularcarcinomapatients AT abdelrahmanelnaggar efficacyandsafetyofsorafenibversussupportivecareinegyptianadvancedhepatocellularcarcinomapatients |